213 related articles for article (PubMed ID: 20854257)
1. Antifolate inhibitors of thymidylate synthase as anticancer drugs.
JarmuĊa A
Mini Rev Med Chem; 2010 Nov; 10(13):1211-22. PubMed ID: 20854257
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer.
Van Triest B; Peters GJ
Oncology; 1999 Oct; 57(3):179-94. PubMed ID: 10545786
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I.
Gangjee A; Jain HD; Kurup S
Anticancer Agents Med Chem; 2007 Sep; 7(5):524-42. PubMed ID: 17896913
[TBL] [Abstract][Full Text] [Related]
4. Anticancer antifolates: current status and future directions.
McGuire JJ
Curr Pharm Des; 2003; 9(31):2593-613. PubMed ID: 14529544
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II.
Gangjee A; Jain HD; Kurup S
Anticancer Agents Med Chem; 2008 Feb; 8(2):205-31. PubMed ID: 18288923
[TBL] [Abstract][Full Text] [Related]
6. Future potential of thymidylate synthase inhibitors in cancer therapy.
Lehman NL
Expert Opin Investig Drugs; 2002 Dec; 11(12):1775-87. PubMed ID: 12457437
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
8. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.
Gonen N; Assaraf YG
Drug Resist Updat; 2012 Aug; 15(4):183-210. PubMed ID: 22921318
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR studies on quinazoline antifolate thymidylate synthase inhibitors by CoMFA and CoMSIA models.
Srivastava V; Gupta SP; Siddiqi MI; Mishra BN
Eur J Med Chem; 2010 Apr; 45(4):1560-71. PubMed ID: 20153089
[TBL] [Abstract][Full Text] [Related]
10. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
11. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
Van Triest B; Pinedo HM; Giaccone G; Peters GJ
Ann Oncol; 2000 Apr; 11(4):385-91. PubMed ID: 10847455
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).
Jones RJ; Twelves CJ
Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of novel antifolate analogs as potential anticancer treatment.
Stoicescu DF; Rotaru M
Anticancer Agents Med Chem; 2013 Feb; 13(2):364-72. PubMed ID: 23157590
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside.
Chu E; Callender MA; Farrell MP; Schmitz JC
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S80-9. PubMed ID: 12819937
[TBL] [Abstract][Full Text] [Related]
16. Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines.
Giudice S; Benassi L; Bertazzoni G; Veratti E; Morini D; Azzoni P; Costi MP; Venturelli A; Pirondi S; Seidenari S; Magnoni C
Invest New Drugs; 2012 Aug; 30(4):1484-92. PubMed ID: 21881917
[TBL] [Abstract][Full Text] [Related]
17. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Assaraf YG
Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
[TBL] [Abstract][Full Text] [Related]
18. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
Jackman AL; Melin CJ; Kimbell R; Brunton L; Aherne GW; Theti DS; Walton M
Biochim Biophys Acta; 2002 Jul; 1587(2-3):215-23. PubMed ID: 12084463
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthase inhibitors.
Danenberg PV; Malli H; Swenson S
Semin Oncol; 1999 Dec; 26(6):621-31. PubMed ID: 10606255
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed disodium (Eli Lilly).
Norman P
Curr Opin Investig Drugs; 2001 Nov; 2(11):1611-22. PubMed ID: 11763166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
